PMID- 10414371
OWN - NLM
STAT- MEDLINE
DCOM- 19990827
LR  - 20190905
IS  - 0393-2990 (Print)
IS  - 0393-2990 (Linking)
VI  - 15
IP  - 4
DP  - 1999 Apr
TI  - Serum IgG antibodies to human herpesvirus-6 (HHV-6) do not predict the 
      progression of HIV disease to AIDS. Italian Seroconversion Study group.
PG  - 317-22
AB  - OBJECTIVES: To evaluate if different levels of human herpesvirus 6 (HHV-6) 
      antibodies can predict HIV disease progression. DESIGN: Longitudinal study of 
      individuals with a documented date of HIV seroconversion. SETTING: Clinical 
      centers located throughout Italy. PATIENTS: Individuals who serconverted for HIV 
      between 1983 and 1995 in Italy. METHODS: Sera were tested for IgG antibodies to 
      HHV-6 using a commercial enzyme immunoassay. A serum sample with an optical 
      density (OD) > or =242 (i.e. the mean value of 10 negative controls +4x standard 
      deviation) was considered as HHV-6 positive; the progression of HIV disease was 
      evaluated estimating the relative hazards (RH) of AIDS (by Cox models) for 
      individuals with higher levels vs. lower levels of HHV-6 antibodies or 
      considering levels of antibodies based on 10% increase of the distribution 
      (deciles). Rates of CD4 decline fitting linear regression were also estimated. 
      RESULTS: A total of 381 persons were followed for a median time of 4 years 
      (range: 0.15-9 years) following the date of collection of the serum sample. The 
      median OD value of HHV-6 antibodies was 306, with an interquartile range of 
      241-440 and a range of 48-2330. A slight inverse correlation was found between 
      HHV-6 antibody levels and age of the individual at the time of serum collection 
      (Spearman rank correlation coefficient, -0.16; p = 0.0013). No association was 
      found between HHV-6 and CD4 level or between HHV-6 and CD8 level at the date of 
      serum collection. The unadjusted RH of progression to AIDS was 0.63 (95% CI: 
      0.42-0.96) for HHV-6 positive individuals vs. HHV-6 negative; when adjusting for 
      possible confounders (CD4, age, pre-AIDS HIV-related pathologies at the date of 
      sera collection, and previous anti-herpes treatment), the RH of AIDS increased to 
      0.80 (95% CI: 0.51-1.23). No particular association with HIV disease progression 
      was found when using the deciles of the distribution of HHV-6 antibodies. The 
      median CD4 cell loss was 5.0x10(6) cells/l per month among HHV-6 positive 
      individuals and 5.7x10(6) cells/l per month among the others. CONCLUSIONS: The 
      presence of high levels of HHV-6 antibodies does not seem to predict the clinical 
      or immunologic progression of HIV disease.
FAU - Dorrucci, M
AU  - Dorrucci M
AD  - Centro Operativo AIDS - Istituto Superiore di Sanita, Rome, Italy.
FAU - Rezza, G
AU  - Rezza G
FAU - Andreoni, M
AU  - Andreoni M
FAU - Pezzotti, P
AU  - Pezzotti P
FAU - Nicastri, E
AU  - Nicastri E
FAU - Ventura, L
AU  - Ventura L
FAU - Zignani, M
AU  - Zignani M
FAU - Alliegro, M B
AU  - Alliegro MB
FAU - Tarantini, G
AU  - Tarantini G
FAU - Salassa, B
AU  - Salassa B
FAU - Colangeli, V
AU  - Colangeli V
FAU - Mazzarello, G
AU  - Mazzarello G
FAU - Ursitti, M A
AU  - Ursitti MA
FAU - Barbanera, M
AU  - Barbanera M
FAU - Pristera, R
AU  - Pristera R
FAU - Castelli, F
AU  - Castelli F
FAU - Ortona, L
AU  - Ortona L
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Epidemiol
JT  - European journal of epidemiology
JID - 8508062
RN  - 0 (Antibodies, Viral)
RN  - 0 (CD4 Antigens)
RN  - 0 (CD8 Antigens)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*immunology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies, Viral/*blood
MH  - CD4 Antigens/analysis
MH  - CD8 Antigens/analysis
MH  - Disease Progression
MH  - HIV Infections/*immunology
MH  - HIV Seropositivity
MH  - Herpesvirus 6, Human/*immunology
MH  - Humans
MH  - Immunoglobulin G/*analysis
MH  - Longitudinal Studies
MH  - Middle Aged
EDAT- 1999/07/22 00:00
MHDA- 1999/07/22 00:01
CRDT- 1999/07/22 00:00
PHST- 1999/07/22 00:00 [pubmed]
PHST- 1999/07/22 00:01 [medline]
PHST- 1999/07/22 00:00 [entrez]
AID - 10.1023/a:1007503018729 [doi]
PST - ppublish
SO  - Eur J Epidemiol. 1999 Apr;15(4):317-22. doi: 10.1023/a:1007503018729.